Abstract
Background:
Distal-type chronic thromboembolic pulmonary hypertension (CTEPH) is a fatal disease for which a new therapeutic strategy needs to be developed. We examined the effects of percutaneous transluminal pulmonary angioplasty (PTPA).
Methods and results:
We prospectively enrolled 12 patients with distal-type CTEPH. After stabilizing their condition with pulmonary vasodilators, we then performed PTPA, which markedly improved pulmonary hemodynamics and pulmonary artery structure, as confirmed by angiography and optical coherence tomography, and also significantly improved their long-term prognosis compared with 39 historical controls.
Conclusions:
PTPA is a promising therapeutic option for distal-type CTEPH.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Angioplasty / methods*
-
Antihypertensive Agents / therapeutic use
-
Bosentan
-
Chronic Disease
-
Combined Modality Therapy
-
Epoprostenol / analogs & derivatives
-
Epoprostenol / therapeutic use
-
Female
-
Humans
-
Hypertension, Pulmonary / drug therapy
-
Hypertension, Pulmonary / physiopathology*
-
Hypertension, Pulmonary / therapy*
-
Male
-
Middle Aged
-
Piperazines / therapeutic use
-
Prognosis
-
Prospective Studies
-
Pulmonary Circulation / drug effects
-
Pulmonary Circulation / physiology*
-
Purines / therapeutic use
-
Sildenafil Citrate
-
Sulfonamides / therapeutic use
-
Sulfones / therapeutic use
-
Treatment Outcome
-
Vasodilator Agents / therapeutic use
Substances
-
Antihypertensive Agents
-
Piperazines
-
Purines
-
Sulfonamides
-
Sulfones
-
Vasodilator Agents
-
beraprost
-
Sildenafil Citrate
-
Epoprostenol
-
Bosentan